A study of advanced non‐small cell lung cancer found that the presence of KRAS mutations (G12X, codon 13 and Q61H) was associated with better survival in ≥ 50% of PD‐L1 patients treated with immune checkpoint inhibitor monotherapy, while there was no significant survival difference in patients treated with chemoimmunotherapy [27]. This evidence concerns the gene KRAS and lung cancer.